Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
398.3 SEK | -0.23% | +0.45% | +38.48% |
May. 08 | Mycronic AB Approves Dividend, Payable on May 16, 2024 | CI |
Apr. 30 | Mycronic AB Receives Order for Two SLX Mask Writers | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 25.08 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Semiconductor Equipment & Testing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+38.48% | 3.6B | B- | ||
+23.47% | 357B | B | ||
+16.51% | 119B | B | ||
+39.50% | 102B | B+ | ||
+10.37% | 19.89B | B+ | ||
+49.31% | 11.25B | B | ||
+30.09% | 9.44B | B+ | ||
+0.09% | 8.2B | C+ | ||
-26.63% | 5.85B | D+ | ||
+31.74% | 5.21B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYCR Stock
- Ratings Mycronic AB